Insilico Medicine announced an agreement with National Laboratory Astana, Nazarbayev University, one of the most rapidly growing universities in the world to collaboratively study aging and age-associated pathologies.
"We are very happy to collaborate with Insilico Medicine, one of the leaders in applying artificial intelligence to aging research. At the Nazarbayev University we are generating vast amounts of data, including next generation sequencing, gut microbiome, genomic and metabolomic data. Healthy aging and healthspan extension is one of our main research priorities. Deep learning has revolutionized many areas including image and text recognition and is likely to advance many areas of biomedicine," said Zhaxybay Zhumadilov, General Director of the National Laboratory Astana, Nazarbayev University.
In the scope of the agreement, Insilico Medicine will provide advanced signaling pathway activation analysis services to evaluate differential changes between healthy tissues and those affected by disease as well as comparing tissues of different ages. In addition to signaling pathway analysis, parties intend to develop artificially-intelligent comprehensive biomarkers of human aging based on large sample data sets.
"Nazarbayev University is one of the most advanced universities in Eastern Europe and Central Asia with state of the art equipment and highly qualified staff educated in top international universities. This institution is scouting for cutting-edge technologies and Insilico Medicine is delighted to be selected as one of the providers of high-technology solutions for longevity research," said Alex Zhavoronkov, CEO of Insilico Medicine. Inc, who was one of the speakers of the recently past the IV International conference on regenerative medicine and healthy aging, held at the National Laboratory Astana on 11-12 May, 2016.
BICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD